Elicio Therapeutics, Inc. (ELTX)
NasdaqCM · USD · Healthcare · Biotechnology
$1.66 (-2.35%) as of
Key statistics
- Market cap
- 44.97M
- Forward P/E
- -0.98
- EPS (TTM)
- -1.9200
- Dividend yield
- 0.00%
- 52-week range
- 1.4400 – 16.0000
- Beta
- 1.98
- Profit margin
- 0.00%
- Analyst target
- $13.67
- Volume
- 106.64k
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.